trenbolone acetate
Topkey Pharmaceutical Chemical Manufacturers - TopkeyChem
Email:info@topkeychem.com

Tel: 86-136-888-53671
Fax: 86-136-888-53671
E-mail: info@topkeychem.com
Feedback
Catalogue of Amino Acid
Catalogue of Steroids
2014 China API Fair

News

Nandrolone Decanoate in Chronic Kidney Disease


Nandrolone Decanoate

Testosterone is an important anabolic hormone that maintains skeletal muscle mass. Male patients with ESRD have low testosterone levels, which is associated with inflammation and mortality.134 Johansen et al. performed two clinical trials to investigate the effect of androgen therapy on body composition and muscle function in patients on dialysis. Patients treated with
nandrolone decanoate, an anabolic steroid, had significant increases in lean body mass along with decreased time to complete walking, stair climbing, and treadmill activities compared to a placebo group.135 The other clinical trial investigated the effects of resistance exercise along with nandrolone decanoate treatment on change in lean body mass (LBM) measured by DEXA and quadriceps muscle cross-sectional area measured by MRI. Sixty-eight dialysis patients were randomized using a 2 by 2 factorial design, with 17 patients receiving nandrolone decanoate injections (women: 100 mg; men 200 mg), 16 patients receiving placebo injections, 19 patients participating in low extremity resistance exercise training (ankle weights), and 16 patients receiving nandrolone decanoate injections and participating in resistance exercise for 12 weeks.136 LBM was significantly increased in the nandrolone decanoate group (3.1±2.2 kg; P<0.0001), but not in the exercise group. There was no significant additional increase in LBM for those patients in the nandrolone decanoate with exercise group. However, there was an increase in quadriceps muscle cross-sectional area in the exercise group. These results indicate that androgen therapy is associated with an increase in lean body mass and may be a beneficial treatment to prevent muscle catabolism in patients with ESRD and PEW.

Preliminary evidence in patients with CKD shows that testosterone treatment improves LBM. Sixteen patients were randomized to receive an intramuscular injection of 100 mg of 
nandrolone decanoate for 3 months while 13 patients served as the control group and received conventional care.122 The treatment group had increased percentage of LBM compared to the control group (4.2%±1.5%, CI=2–8; P<0.05). Further studies are warranted in patients with CKD, but must take into account the potential side-effects of testosterone treatment.

Go Back 】 | 【 Print 】 | 【 Close this window

Online Support

Skype